Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Recommendation of “Hold” from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given an average recommendation of “Hold” by the twenty-two analysts that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $124.15.

A number of research firms have recently issued reports on ZBH. Raymond James reduced their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Stifel Nicolaus increased their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Truist Financial reiterated a “hold” rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, Barclays decreased their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently bought and sold shares of ZBH. Menard Financial Group LLC acquired a new position in Zimmer Biomet in the fourth quarter worth $30,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Zimmer Biomet during the 4th quarter worth about $14,432,000. Jefferies Financial Group Inc. grew its holdings in Zimmer Biomet by 28.4% during the 4th quarter. Jefferies Financial Group Inc. now owns 18,680 shares of the medical equipment provider’s stock worth $1,973,000 after acquiring an additional 4,133 shares during the last quarter. Integrated Advisors Network LLC increased its position in Zimmer Biomet by 12.3% in the 4th quarter. Integrated Advisors Network LLC now owns 4,022 shares of the medical equipment provider’s stock valued at $425,000 after acquiring an additional 441 shares in the last quarter. Finally, Ameriflex Group Inc. bought a new position in shares of Zimmer Biomet in the fourth quarter worth about $70,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

ZBH opened at $104.32 on Monday. The firm has a market capitalization of $20.77 billion, a P/E ratio of 23.44, a PEG ratio of 1.95 and a beta of 1.02. The stock has a fifty day moving average of $105.72 and a 200-day moving average of $107.36. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet has a 12-month low of $97.69 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the business earned $2.20 EPS. Equities analysts forecast that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.92%. Zimmer Biomet’s dividend payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.